Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 313

1.

Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.

Beck EM, Cavelti M, Kvrgic S, Kleim B, Vauth R.

Schizophr Res. 2011 Oct;132(1):42-9. doi: 10.1016/j.schres.2011.07.019. Epub 2011 Aug 5.

PMID:
21820875
2.

Do patients with schizophrenia distinguish between attitudes toward antipsychotic medication and pharmacotherapy in general? Validation of the Beliefs About Medication Questionnaire.

Beck EM, Vögelin R, Wirtz M, Cavelti M, Kvrgic S, Vauth R.

J Nerv Ment Dis. 2012 Jan;200(1):33-43. doi: 10.1097/NMD.0b013e31823e5875.

PMID:
22210360
3.

Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.

Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, Poyurovsky M.

Schizophr Res. 2011 Aug;130(1-3):176-81. doi: 10.1016/j.schres.2011.04.030. Epub 2011 Jun 1. Erratum in: Schizophr Res.2013 May;146(1-3):379.

PMID:
21636254
4.

Treatment adherence and insight in schizophrenia.

Bitter I, Fehér L, Tényi T, Czobor P.

Psychiatr Hung. 2015;30(1):18-26.

PMID:
25867885
5.

How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.

Beck EM, Cavelti M, Wirtz M, Kossowsky J, Vauth R.

Psychiatry Res. 2011 May 15;187(1-2):55-61. doi: 10.1016/j.psychres.2010.10.012. Epub 2010 Nov 12.

PMID:
21074860
6.

Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.

Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, Healy D, Rae P, Power C.

Arch Gen Psychiatry. 2005 Jul;62(7):717-24.

PMID:
15997012
7.

Attitudes toward antipsychotic medication, insight and psychopathology in outpatients with schizophrenia.

Vassileva IV, Milanova VK.

Folia Med (Plovdiv). 2012 Oct-Dec;54(4):62-8.

PMID:
23441471
8.

Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study.

Bressington D, Mui J, Gray R.

Int J Ment Health Nurs. 2013 Feb;22(1):35-46. doi: 10.1111/j.1447-0349.2012.00830.x. Epub 2012 Jun 27.

PMID:
22738372
9.

Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.

Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC.

J Clin Psychiatry. 2004 Oct;65(10):1372-6.

PMID:
15491241
10.

[Drug compliance and health locus of control in schizophrenia].

Combes C, Feral F.

Encephale. 2011 May;37 Suppl 1:S11-8. doi: 10.1016/j.encep.2010.08.007. Epub 2010 Oct 8. French.

PMID:
21600328
11.

A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral.

Patel MX, de Zoysa N, Bernadt M, David AS.

J Clin Psychiatry. 2008 Oct;69(10):1548-56. Epub 2008 Sep 23.

PMID:
19192437
12.

Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.

Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA.

Schizophr Bull. 2009 Mar;35(2):336-46. doi: 10.1093/schbul/sbn067. Epub 2008 Jun 26.

13.

Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.

Yang J, Ko YH, Paik JW, Lee MS, Han C, Joe SH, Jung IK, Jung HG, Kim SH.

Schizophr Res. 2012 Feb;134(2-3):226-31. doi: 10.1016/j.schres.2011.11.008. Epub 2011 Nov 30.

PMID:
22133906
14.

Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics.

Yalcin-Siedentopf N, Wartelsteiner F, Kaufmann A, Biedermann F, Edlinger M, Kemmler G, Rettenbacher MA, Widschwendter CG, Zernig G, Fleischhacker WW, Hofer A.

Int J Neuropsychopharmacol. 2014 Dec 7;18(5). pii: pyu091. doi: 10.1093/ijnp/pyu091.

15.

Control beliefs, therapeutic relationship, and adherence in schizophrenia outpatients: a cross-sectional study.

Jaeger S, Weißhaupt S, Flammer E, Steinert T.

Am J Health Behav. 2014 Nov;38(6):914-23. doi: 10.5993/AJHB.38.6.13.

PMID:
25207516
16.

Medication adherence and subjective weight perception in patients with first-episode psychotic disorder.

Wong MM, Chen EY, Lui SS, Tso S.

Clin Schizophr Relat Psychoses. 2011 Oct;5(3):135-41. doi: 10.3371/CSRP.5.3.3.

PMID:
21983497
17.

Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.

Brain C, Allerby K, Sameby B, Quinlan P, Joas E, Karilampi U, Lindström E, Eberhard J, Burns T, Waern M.

Eur Neuropsychopharmacol. 2013 Dec;23(12):1754-62. doi: 10.1016/j.euroneuro.2013.09.001. Epub 2013 Sep 19.

PMID:
24091164
18.

Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.

Barbui C, Kikkert M, Mazzi MA, Becker T, Bindman J, Schene A, Nosè M, Helm H, Thornicroft G, Tansella M.

Psychopathology. 2009;42(5):311-7. doi: 10.1159/000232973. Epub 2009 Aug 11.

PMID:
19672133
19.

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.

Ascher-Svanum H, Weiden P, Nyhuis AW, Faries DE, Stauffer V, Kollack-Walker S, Kinon BJ.

Clin Schizophr Relat Psychoses. 2014 Jul;8(2):84-90, 90A. doi: 10.3371/CSRP.ASWE.022213.

PMID:
23446198
20.

Relationships among medication adherence, insight, and neurocognition in chronic schizophrenia.

Na E, Yim SJ, Lee JN, Kim JM, Hong K, Hong MH, Han H.

Psychiatry Clin Neurosci. 2015 May;69(5):298-304. doi: 10.1111/pcn.12272. Epub 2015 Mar 9.

Supplemental Content

Support Center